Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (any subtype) that has been confirmed by a tissue or needle biopsy, and whose cancer is either at an advanced stage (Stage IV) or has come back after earlier treatment.
• People who have already received at least one round of treatment for their lung cancer and whose cancer has since gotten worse, OR people who are currently being treated for advanced or returned cancer and have received at least one dose of their current treatment.
• People whose cancer has progressed after receiving certain types of treatment — either a platinum-based chemotherapy or an immunotherapy drug (such as nivolumab or pembrolizumab) — at some point during their treatment history.
• People who have certain specific gene changes in their cancer (such as EGFR, ALK, ROS1, or BRAF mutations) may still be considered, as long as all standard targeted treatments for those gene changes have already been tried and the cancer continued to progress.
• People who are 18 years of age or older.
• People who have enough suitable tumour tissue available for testing, as confirmed by a local pathologist before registration (the tissue sample must meet specific size and quality requirements set by the trial).
• People who are in good general physical condition, rated 0 or 1 on a standard performance scale used by doctors, assessed within 28 days before joining (confirm with trial site).
• People who are willing to have their tumour tissue sent to a specialised laboratory for broad genetic and biomarker testing.
• People who are willing to share their smoking history as part of the study forms.
• People who are willing to have any leftover tissue stored for future research studies connected to this trial.
• People who have given written informed consent, confirming they understand the investigational nature of the trial.

Who may not be able to join:

• People whose cancer has certain specific gene changes (EGFR, ALK, ROS1, or BRAF) and who have not yet completed all standard targeted therapies available for those gene changes.
• People whose prior treatment was only for early-stage disease (Stages I–III) and whose cancer did not progress within one year of finishing that treatment (confirm with trial site).
• People whose tumour tissue sample does not meet the minimum quality or quantity requirements set by the trial.
• People whose only available tissue sample comes from a bone biopsy, as bone biopsies are not accepted for this trial.
• People who are in a physical condition rated lower than the required performance level (rated 2 or above on the doctor's scale) at the time of registration.
• People whose treating institution does not have current ethical approval for this study on record.

Important: Always verify eligibility with the trial site directly before applying.